Danish drugmaker Novo Nordisk has released fresh clinical data on two of its lead investigational assets, seeking to bolster ...

Armed with an asset that could be an improvement on Pfizer’s blockbuster smoking cessation drug Chantix/Champix (varenicline) ...

In June 2025, Cycle received FDA approval for HARLIKU (nitisinone) tablets for alkaptonuria (AKU), a rare metabolic disorder ...

Geopolitics, medicines and European legislation – it all came together during a special AXON-Bruggink session on the position of the Netherlands as a location for innovative medicines, according to ...

Notable research news last week included Sarepta Therapeutics reporting another death associated with a trial of its Duchenne ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Hetronifly (serplulimab) to treat adults ...

US biotech Actio Biosciences has raised $66 million in a series B round to support its pipeline of genetically targeted ...

At a time when Novo Nordisk has appeared to be slipping behind rival Eli Lilly and its blockbuster Zepbound (tirzepatide) in ...

Private Equity - a subsidiary of Turkey's İşbank Group - has committed $39 million to a Harvard University research lab to ...

Privately-held UK firm Cycle Pharmaceuticals announced that the US Food and Drug Administration (FDA) has approved Harliku ...

US healthcare group Abbott (NYSE: ABT) has signed a wide-ranging agreement with health authorities in Abu Dhabi to localize ...

Zealand Pharma, a Danish firm focused on the discovery and development of innovative peptide-based medicines, has announced ...